Markets
markets
Luke Kawa

CoreWeave’s post-earnings surge disappears after guidance fails to validate the >100% rally

Shares of CoreWeave surged as much as 11% in the wake of its inaugural quarterly report as a publicly traded company, with the cloud computing company posting better-than-expected sales and touting a massive revenue backlog tied to its deal with OpenAI.

But that post-earnings pop fizzled less than 30 minutes into the conference call, with the stock turning well into the red and now trading virtually flat in the premarket on Thursday.

On the surface, the guidance unveiled on the call was just fine: the outlook for Q2 and full-year sales topped estimates, though adjusted operating income for the current quarter was light relative to expectations. But there are times when “just fine” clearly isn’t good enough. We’ve seen a similar dynamic with Nvidia during recent quarters, where solid earnings beats and better-than-expected guidance fail to inspire a big rally in the shares.

The after-hours high-water mark for CoreWeave propelled the stock more than 110% off its lows seen less than a month ago. Climbing a mountain gets a lot more difficult after an already brisk ascent brings you to previously unforeseen heights. Steep inclines at high elevations with thinning oxygen leave you more vulnerable to accidents.

Case in point: a handful of Wall Street outfits are raising their price target on the stock in the wake of these results — Morgan Stanley to $58, Wells Fargo to $60, Barclays and Mizuho to $70, and Stifel to $75. What all of those have in common is that none of them are above the stock’s post-earnings peak of $75.

(Separately, BofA boosted its price target to $76, a buck above the stock’s top level in the after-hours session, while DA Davidson cut the stock to “underperform” with a $36 price target.)

More Markets

See all Markets
markets

Spectrum owner Charter Communications is on pace for its worst day ever as broadband numbers and Q1 results disappoint

Cable and broadband company Charter Communications is on pace for its worst-ever trading day on Friday, as investors dump the stock following its Q1 results and forward guidance.

Charter, which owns Spectrum, reported adjusted earnings of $9.17 per share, below Wall Street estimates of $9.96 per share from analysts polled by FactSet. On the company’s earnings call, CFO Jessica Fischer appeared to lower its guidance for full-year revenue per user.

“It’ll be close either way in terms of whether we end up with net growth,” Fischer said.

The company lost 120,000 internet subscribers in the quarter, deeper than the expected 94,800 and double its loss from the same period last year. That news comes one day after Comcast’s earnings provided a bit of optimism for broadband as a category: the company reported Q1 losses of 65,000, significantly improving from 183,000 losses in the same quarter last year. Comcast is down more than 10%, on pace for its worst day since January 2025.

markets

Nvidia poised to snap longest run without a record close since the AI boom began

The stock price of the company responsible for the brains of the AI boom is finally showing some brawn again.

Nvidia, the world’s most valuable company, is poised to close at a record high for the first time since October 29, 2025, on Friday (if it ends above $207.04).

The AI chip trade is on fire, with the Philadelphia Semiconductor Index slated to deliver its 18th consecutive gain as Intel’s robust results and outlook juice the entire ecosystem. Hyperscalers report earnings next week, and their capex guidance can be thought of as the earnings guidance for Nvidia and other AI suppliers for the quarters to come.

This would end Nvidia’s longest stretch without a record close since the unofficial start of the AI boom (when the chip designer delivered blowout quarterly results in May 2023).

(Sorry if I jinx this!)

markets

Lilly slips after prescriptions for its weight-loss pill come in below expectations in second week

Eli Lilly fell on Friday after prescription data for its new weight-loss pill, Foundayo, showed that it’s having a significantly slower rollout than its top competitor.

The pill was prescribed about 3,700 times in its second week, according to IQVIA data cited by Deutsche Bank analysts, compared to the roughly 8,000 they were expecting. Novo Nordisk’s Wegovy pill, which came out in January, hit over 18,000 prescriptions in its second week.

The FDA approved Foundayo on April 1 and shipments began on April 9. Deutsche analysts noted that Lilly’s GLP-1 injections, which currently outsell Novo’s, also had a slower start.

Lilly fell more than 4% after the numbers were released. Novo Nordisk rose more than 5%.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.